Nanomedicine has been extensively explored to enhance the efficacy of chemotherapy with
modest therapeutic efficacy in the clinic, owing to various factors. A primary factor is …

Current cancer nanomedicines can only mitigate adverse effects but fail to enhance
therapeutic efficacies of anticancer drugs. Rational design of next‐generation cancer …

Lipid nanoparticle-mediated RNA delivery holds great potential to treat various liver
diseases. However, targeted delivery of RNA therapeutics to activated liver-resident …

Coating the nanoparticle surface with cancer cell recognizing ligands is expected to facilitate
specific delivery of nanoparticles to diseased cells in vivo. While this targeting strategy is …

The impermeable barrier of solid tumors due to the complexity of their components limits the
treatment effect of nanomedicine and hinders its clinical translation. Several methods are …

The interface of bio–nano science and cancer medicine is an area experiencing much
progress but also beset with controversy. Core concepts of the field eg, the enhanced …

Nanotechnology in medical applications, especially in oncology as drug delivery systems,
has recently shown promising results. However, although these advances have been …

The widespread development of nanocarriers to deliver chemotherapeutics to specific tumor
sites has been motivated by the lack of selective targeting during chemotherapy inducing …

Cancer immunotherapies that harness the body's immune system to combat tumors have
received extensive attention and become mainstream strategies for treating cancer. Despite …

Using nanoparticles to carry and delivery anticancer drugs holds much promise in cancer
therapy, but nanoparticles per se are lacking specificity. Active targeting, that is, using …